Anifrolumab

Drug Profile

Anifrolumab

Alternative Names: Anti-IFNaR MAb - Medarex/MedImmune; MDX-1333; MEDI-546

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Medarex
  • Developer Medarex; MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action Interferon alpha beta receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Systemic lupus erythematosus
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Systemic lupus erythematosus
  • No development reported Scleroderma

Most Recent Events

  • 06 Jun 2016 AstraZeneca plans the extension phase III TULIP SLE LTE trial for Systemic lupus erythematosus in Bulgaria, Belgium, Czech Republic, Germany, Lithuania, Russia, Spain, Canada, Singapore, USA, France, South Korea, Argentina, South Africa, Mexico, Australia, New Zealand, Romania, Israel, Taiwan, Ukraine, Italy, Brazil, Chile, Colombia, Peru, Hungary and Poland (IV) (NCT02794285)
  • 01 Jun 2016 AstraZeneca initiates the extension phase III TULIP SLE LTE trial for Systemic lupus erythematosus in USA (IV) (NCT02794285)
  • 31 May 2016 AstraZeneca completes a phase I trial in Healthy volunteers in USA (IV, infusion) (NCT02601625)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top